Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients

Eric Wooltorton
CMAJ September 02, 2003 169 (5) 446;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Metrics
  • Responses
  • PDF
Loading

Reason for posting: Mood and anxiety disorders are often managed with selective serotonin reuptake inhibitors (SSRIs) such as paroxetine because of their presumed efficacy and positive safety profile.1,2,3,4 However, recent placebo-controlled trials have revealed concerns about paroxetine's efficacy and safety in the pediatric population. These concerns led the drug's manufacturer, GlaxoSmithKline, to issue “Dear Health Care Professional” letters in several countries, including the United States, the United Kingdom and Canada.5

The drug: Paroxetine is the ninth most commonly prescribed drug in Canada, with over 3 million prescriptions filled in 2002 (www.imshealthcanada.com/htmen/1_0_5.htm). It is a potent 5-HT receptor inhibitor and is partly metabolized by cytochrome P450 (2D6).6 It is indicated for the treatment of depression, obsessive–compulsive disorder, panic disorder, social phobia, generalized anxiety disorder and post-traumatic stress disorder in adults6 and is often used off-label in pediatric populations.5

The US Food and Drug Administration recently reviewed additional safety and efficacy data for the use of paroxetine in pediatric populations (www.fda.gov/bbs/topics/ANSWERS/2003/ANS01230.html). The pooled results of 3 unpublished trials involving pediatric patients with major depressive disorder failed to show paroxetine to be more efficacious than placebo.5 In addition, the pooled results showed that suicidal thoughts, suicide attempts and episodes of self-harm were more frequent among the paroxetine users (5.3% of 378 children) than among those in the placebo group (2.8% of 285 children).5 In a separate placebo-controlled trial involving children with social anxiety disorder, 2.4% of the 165 children given paroxetine had suicide-related adverse events as compared with none of 157 children given a placebo.5 The safety of the drug in the contexts of social anxiety disorder and obsessive–compulsive disorder in children and adolescents is currently being investigated further.

No completed suicides have been reported in GlaxoSmithKline's pediatric clinical trial program for children taking paroxetine, nor have any been reported in Canada. About 1% of the paroxetine-associated pediatric adverse events reported to Health Canada between 1993 and Apr. 30, 2003, were because of suicidal ideation.

What to do: Paroxetine is contraindicated for patients under the age of 18. Although patients with mood disorders often require careful supervision because of an inherent risk of suicide, any pediatric patient currently taking paroxetine should be screened for suicidal thoughts, suicide attempts or episodes of self-harm. Serious consideration should be given to changing therapies in all pediatric patients except those who have nearly completed successful courses. The drug should not be discontinued abruptly (this can lead to serious SSRI withdrawal symptoms);7 rather, a gradual tapering of the dose is recommended. The relative safety of other antidepressants and SSRIs in pediatric populations is unclear. The current warnings do not apply to adult users of paroxetine.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Remick RA. Diagnosis and management of depression in primary care: a clinical update and review [review]. CMAJ 2002;167(11):1253-60.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Hazell P. Depression in children and adolescents [review]. Am Fam Physician 2003;67(3):577-9.
    OpenUrlPubMed
  3. 3.↵
    Son SE, Kirchner JT. Depression in children and adolescents. Am Fam Physician 2000;62(10):2297-308, 2311-2.
    OpenUrlPubMed
  4. 4.↵
    Ryan ND. Medication treatment for depression in children and adolescents. CNS Spectr 2003;8:283-7.
    OpenUrlPubMed
  5. 5.↵
    Important drug warning: Until further information is available, Paxil® (paroxetine hydrochloride) should not be used in children and adolescents under 18 years of age [Dear Health Care Professional Letter]. Mississauga (ON): GlaxoSmithKline Inc.; July 2003. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/paxil_e.html (accessed 2003 Aug 5).
  6. 6.↵
    Paxil [product monograph]. In: Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2003. p. 1255-60.
  7. 7.↵
    Green B. Focus on paroxetine. Curr Med Res Opin 2003;19(1):13-21.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (5)
CMAJ
Vol. 169, Issue 5
2 Sep 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Eric Wooltorton
CMAJ Sep 2003, 169 (5) 446;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Eric Wooltorton
CMAJ Sep 2003, 169 (5) 446;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Facing the evidence: antidepressant treatment in children and adolescents
  • Google Scholar

More in this TOC Section

Practice

  • Tocilizumab for hospitalized patients with COVID-19
  • A 59-year-old man with persistent fever, aphasia and leg pain
  • Gelatinous pseudocysts in cryptococcal infection of the central nervous system
Show more Practice

Health and Drug Alerts

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Psychiatry & mental health: child & adolescent
    • Suicide
    • Psychiatry & mental health: adult
    • Drugs: psychotherapeutic
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, CMA Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire